Patient presents with symptoms suggestive of pulmonary tuberculosis (TB), including persistent cough, productive of sputum occasionally blood-tinged (hemoptysis), fever, chills, night sweats, fatigue, and unintentional weight loss.  The patient reports a history of potential exposure to tuberculosis.  Physical examination reveals decreased breath sounds and dullness to percussion in the right upper lung field.  Differential diagnosis includes pneumonia, bronchitis, lung cancer, and other respiratory infections.  Initial diagnostic workup includes a chest X-ray (CXR) demonstrating apical infiltrates and cavitary lesions consistent with tuberculosis.  Sputum smear microscopy for acid-fast bacilli (AFB) was ordered and is pending.  QuantiFERON-TB Gold test was ordered to assess latent tuberculosis infection (LTBI) status if sputum smear is negative.  Given the clinical presentation and radiographic findings, the patient is presumed to have active pulmonary tuberculosis and has been placed on respiratory isolation precautions pending confirmatory diagnostic testing.  Treatment initiated with standard four-drug antituberculosis therapy consisting of isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB).  Patient education provided regarding medication adherence, infection control measures, and the importance of follow-up appointments.  ICD-10 code A15.0 assigned for pulmonary tuberculosis.  CPT codes for evaluation and management (E/M) services, chest x-ray, and laboratory tests will be documented and billed accordingly.  Public health department notification will be completed per reporting guidelines.  Patient will return for follow-up evaluation and repeat sputum testing in two weeks to assess treatment response and monitor for adverse drug reactions.